Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.
To evaluate the role of apparent diffusion coefficient (ADC) imaging in assessing tumor cell infiltration after treatment with the antivascular endothelial growth factor (anti-VEGF) agent, cediranib, we prospectively analyzed diffusion MRI scans from 30 patients participating in a Phase II trial of cediranib for recurrent glioblastoma. A patient-specific threshold was selected below which ADC values were determined to be abnormally low and suggestive of tumor. We determined the percent of low ADC in the FLAIR hyperintensity surrounding the enhancing tumor and then visualized the location of these low ADC voxels. The percent volume of the FLAIR hyperintensity comprised by low ADC increased significantly from baseline (2.3%) to day 28 (2.9%), day 56 (5.0%), and day 112 (6.3%) of treatment with cediranib suggesting increasing infiltrative tumor in some patients. Visualization of the location of the low ADC voxels suggested regions of tumor growth that were not visible on contrast-enhanced MRI. ADC maps can be used to suggest regions of infiltrative tumor cells with anti-VEGF therapy and should be validated in future studies.
Gerstner
Elizabeth R
ER
Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA. egerstner@partners.org
Chen
Poe-Jou
PJ
Wen
Patrick Y
PY
Jain
Rakesh K
RK
Batchelor
Tracy T
TT
Sorensen
Gregory
G
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology*; D038524:Diffusion Magnetic Resonance Imaging; D018572:Disease-Free Survival; D005909:Glioblastoma / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D016016:Proportional Hazards Models; D011799:Quinazolines / Q000627:therapeutic use*; D007211:Indoles
D000970:Antineoplastic Agents; D011799:Quinazolines; C500926:cediranib; D007211:Indoles
J Clin Oncol. 2008 Jul 10;26(20):3387-94
18541899
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64
16267128
Cancer Res. 2001 Jul 1;61(13):4971-3
11431326
Radiol Clin North Am. 1988 Jul;26(4):873-87
3289078
Clin Cancer Res. 2008 Jun 15;14(12):3832-9
18559603
Neuro Oncol. 2008 Dec;10(6):940-5
18708344
J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36
11121466
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9
15805192
Nat Rev Neurosci. 2007 Aug;8(8):610-22
17643088
Clin Cancer Res. 1997 Sep;3(9):1457-66
9815831
Neurology. 2008 Mar 4;70(10):779-87
18316689
Neuroimaging Clin N Am. 2006 Nov;16(4):619-32, viii-ix
17148023
Nat Clin Pract Oncol. 2008 Nov;5(11):634-44
18711427
Cancer Res. 2006 May 1;66(9):4687-92
16651420
Neoplasia. 2000 Jul-Aug;2(4):306-14
11005565
Cancer Cell. 2007 Jan;11(1):83-95
17222792
J Clin Oncol. 1990 Jul;8(7):1277-80
2358840
Radiology. 2005 Mar;234(3):756-64
15734932
Cancer Res. 2001 Sep 15;61(18):6624-8
11559524
Clin Cancer Res. 2004 Dec 1;10(23):7852-9
15585617
J Clin Oncol. 2003 Mar 15;21(6):1094-100
12637476
Clin Cancer Res. 2007 May 15;13(10):2897-904
17504989
J Clin Oncol. 2001 Jan 15;19(2):551-7
11208850